Caris Life Sciences (CAI) Expands AI Insights Portfolio With Signature to Predict Ovarian Cancer Platinum Resistance [Yahoo! Finance]
Caris Life Sciences, Inc. (CAI)
Last caris life sciences, inc. earnings: 10/29 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.capps.com/investor-relations
Company Research
Source: Yahoo! Finance
Life Sciences expanded its Caris AI Insights portfolio with a new AI signature designed to predict early platinum resistance in patients with high-grade serous ovarian cancer/HGSOC. This tool uses the company's proprietary CodeAI platform to analyze Whole Exome Sequencing/WES, Whole Transcriptome Sequencing/WTS, and clinical data. The signature aims to provide clinicians with molecular foresight into how long a patient might benefit from standard platinum-based chemotherapy before disease progression. HGSOC is an aggressive cancer often diagnosed at advanced stages, with ~20% to 30% of patients experiencing resistance within 6 months of their first treatment. By generating a risk score and classifying patients as platinum-sensitive or platinum-resistant, this technology helps doctors identify those who may need to transition quickly to alternative therapies. This is particularly significant following recent FDA approvals for new combination treatments specifically targeting platin
Show less
Read more
Impact Snapshot
Event Time:
CAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAI alerts
High impacting Caris Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
CAI
News
- Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies [Yahoo! Finance]Yahoo! Finance
- Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies [TheStreet.com]TheStreet.com
- Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid MalignanciesPR Newswire
- Caris Life Sciences (CAI) is now covered by The Goldman Sachs Group, Inc.. They set a "buy" rating and a $27.00 price target on the stock.MarketBeat
- Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect [Yahoo! Finance]Yahoo! Finance
CAI
Earnings
- 2/26/26 - Beat
CAI
Sec Filings
- 4/2/26 - Form 8-K
- 3/10/26 - Form 4
- 3/10/26 - Form 4
- CAI's page on the SEC website